NovoCure (NVCR) Competitors

ICU Medical (NASDAQ:ICUI) and NovoCure (NASDAQ:NVCR) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Do institutionals & insiders have more ownership in ICUI or NVCR?

96.1% of ICU Medical shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 6.7% of ICU Medical shares are held by company insiders. Comparatively, 6.3% of NovoCure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community prefer ICUI or NVCR?

NovoCure received 84 more outperform votes than ICU Medical when rated by MarketBeat users. However, 64.48% of users gave ICU Medical an outperform vote while only 63.71% of users gave NovoCure an outperform vote.

Company	Underperform	Outperform
ICU Medical	Outperform Votes 383 64.48%	Underperform Votes 211 35.52%
NovoCure	Outperform Votes 467 63.71%	Underperform Votes 266 36.29%

Does the media refer more to ICUI or NVCR?

In the previous week, NovoCure had 2 more articles in the media than ICU Medical. MarketBeat recorded 8 mentions for NovoCure and 6 mentions for ICU Medical. NovoCure's average media sentiment score of 1.73 beat ICU Medical's score of 0.82 indicating that ICU Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ICU Medical	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NovoCure	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate ICUI or NVCR?

ICU Medical currently has a consensus price target of $123.00, indicating a potential upside of 17.25%. NovoCure has a consensus price target of $30.88, indicating a potential upside of 38.33%. Given ICU Medical's higher probable upside, analysts plainly believe NovoCure is more favorable than ICU Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICU Medical	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
NovoCure	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

Is ICUI or NVCR more profitable?

ICU Medical has a net margin of -2.63% compared to ICU Medical's net margin of -36.67%. NovoCure's return on equity of 5.38% beat ICU Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICU Medical	-2.63%	5.38%	2.58%
NovoCure	-36.67%	-50.35%	-16.86%

Which has more volatility and risk, ICUI or NVCR?

ICU Medical has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.

Which has preferable earnings & valuation, ICUI or NVCR?

ICU Medical has higher revenue and earnings than NovoCure. ICU Medical is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICU Medical	$2.26B	1.13	-$29.66M	-$2.45	-42.82
NovoCure	$509.34M	4.72	-$207.04M	-$1.81	-12.33

Summary

ICU Medical beats NovoCure on 11 of the 18 factors compared between the two stocks.